CMS Introduces GLOBE Model to Lower Drug Prices for Medicare Beneficiaries

The Centers for Medicare & Medicaid Services (CMS) has taken a significant step towards addressing the rising costs of prescription medications by finalizing the Global Benchmark for Efficient Drug Pricing (GLOBE) Model. Set to commence on January 1, 2027, this innovative five-year initiative is designed to establish a new rebate formula for Part B drug inflation rebates. The GLOBE Model will directly affect a subset of Medicare beneficiaries, roughly 25% of those enrolled in Original Medicare, in specific geographic areas that will be chosen at a later date. The model is intended to test whether this international benchmark-based formula can effectively lower drug costs for beneficiaries while maintaining the quality of care.

This model stems from ongoing efforts to incite change in drug pricing by adopting a more competitive framework that aligns U.S. prices to those seen in economically similar countries. Dr. Mehmet Oz, the CMS Administrator, highlighted that, "Medicare Part B patients and American taxpayers have paid significantly more for prescription medications than people in comparable countries." He emphasized that the GLOBE Model aims not only to ensure more affordable healthcare but also to bolster care quality and medical innovation in the process.

One of the critical aspects of the GLOBE Model is the shift towards an international pricing benchmark for calculating Medicare Part B drug inflation rebate amounts. This adjustment is positioned as a response to the dramatic rise in costs that Original Medicare beneficiaries have experienced in the past decade; specifically, drug spending within Original Medicare has reportedly increased nearly four times faster than overall drug expenditures across various payers from 2008 to 2021.

Rebate invoicing and reconciliation related to the GLOBE Model will carry on until March 31, 2034, giving pharmaceutical companies and healthcare providers ample time to adjust their systems and billing practices in line with the new mandatory model. While testing this approach, the model will exclude certain products such as biosimilars, orphan-only drugs, and some specialized therapies, broadening its focus to widely utilized drugs in the healthcare system.

The implications of the GLOBE Model may be vast for pharmaceutical manufacturers and third-party contractors focusing on billing and invoicing. These entities will need to reassess their operational workflows to accommodate the new calculations for rebates and ensure compliance within all market segments that will be affected by this five-year pilot program. As engagement in this model unfolds, private sector stakeholders in pharmaceuticals and healthcare services are encouraged to begin strategizing for adaptations in ordering and billing processes, potentially leading to lower out-of-pocket costs for patients across the affected areas.

The model's implications for contractors and service providers should not be underestimated, as their responsiveness to procurement changes could be a critical determinant in their future engagements with Medicare-related business. The announcement signifies not just a shift in pricing strategy, but an overarching policy direction aimed at enhancing care accessibility while minimizing out-of-pocket burdens for vulnerable patient populations.

In conclusion, the GLOBE Model serves as not only a necessary intervention aimed at curbing escalating drug costs but also as a significant procurement consideration for stakeholders involved in the healthcare payment ecosystem. Companies involved in encompassing services—from manufacturing to billing—must actively prepare for comprehensive transitions accompanying this shift in policy.

• CMS finalizes the GLOBE Model effective January 1, 2027.
• This model includes a five-year initiative to test new Part B drug rebates.
• Approximately 25% of Original Medicare beneficiaries will be affected by this model.
• Manufacturer invoicing for the GLOBE Model continues until March 31, 2034.
• Dr. Mehmet Oz emphasized a commitment to lowering drug costs and preserving care quality.
• Drug spending in Original Medicare Part B grew nearly four times faster than other payers from 2008-2021.
• The model applies to selected geographic areas, yet specifics are not yet identified.
• Certain drugs will be excluded from the model, such as biosimilars and specific therapies following public comments.